You are viewing the site in preview mode
Skip to main content
| |
N (%)
|
|---|
|
Practice Location
|
|
Academic
|
55 (91)
|
|
Private
|
4 (7)
|
|
Years in practice
| |
|
<5 years
|
18 (30)
|
|
5-10 years
|
17 (28)
|
|
11-15 years
|
9 (15)
|
|
> 15 years
|
16 (27)
|
|
Training
| |
|
Pediatric Rheumatologist
|
56 (93)
|
|
Med/Peds Rheumatologist
|
3 (5)
|
|
Other
|
1 (2)
|
|
Number of JSpA patients seen annually
| |
|
< 5 patients
|
5 (8)
|
|
5-10 patients
|
16 (27)
|
|
>10 patients
|
39 (65)
|
|
Duration before deeming treatment failure
| |
|
2 months
|
4 (7)
|
|
3 months
|
36 (60)
|
|
6 months
|
14 (23)
|
|
Have JSpA patients who failed TNFi therapy in last 2 yrs
|
38 (63)
|
|
Have switched back to same TNFi after failing
|
10 (17)
|
|
Reasons for change anti-TNF therapy:
| |
|
Secondary non-response
|
43 (72)
|
|
Primary non-response
|
35 (58)
|
|
Intolerance
|
29 (48)
|
|
Concomitant disease
|
28 (47)
|
|
Chronic pain
|
15 (25)
|
|
Reasons for primary non-response
| |
|
Arthritis (Sacroiliac joints)
|
27 (45)
|
|
Arthritis (peripheral)
|
16 (27)
|
|
Enthesitis
|
16 (27)
|
|
Pain
|
2 (1)
|
|
Number of anti-TNF agents (total) tried before switching to another class
| |
|
1
|
1 (1.5)
|
|
2
|
37 (62)
|
|
3
|
21(35)
|
|
>3
|
1 (1.5)
|
|
Other medications used after TNFi failure
| |
|
Abatacept
|
24 (40)
|
|
Tocilizumab
|
21 (35)
|
|
Ustekinumab
|
17 (28)
|
|
Secukinumab
|
16 (27)
|
|
Tofacitinib
|
8 (13)
|
|
Rituximab
|
2 (3)
|
|
Other: Apremilast (1), Methotrexate (1), Steroids (1)
| |
